Review
. 2020 Aug; 8(3):.
doi: 10.3390/vaccines8030447.

Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma

Robin Park 1 Fariha Eshrat 2 Mohammed Al-Jumayli 2 Azhar Saeed 3 Anwaar Saeed 2 
Affiliations
  • PMID: 32784389
  •     72 References
  •     8 citations

Abstract

Advanced hepatocellular carcinoma has limited treatment options, but there has been extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, and bevacizumab, which are some of the treatments that have received FDA approval just over the last three years. Because HCC tumor microenvironment is potentially immunogenic and typically characterized by inflammation, immunotherapy has been proposed as a potential novel therapeutic approach, which has prompted studies in advanced HCC patients investigating various immune-therapeutic strategies such as CAR-T cell therapy, checkpoint inhibitors, and onco-vaccines. The anti-PD-1 checkpoint inhibitors nivolumab and pembrolizumab have been FDA approved as a second line treatment in patients who progressed or are intolerant to Sorafenib. To build up on the success of PD-1 monotherapy, combinatorial regimens with PD-1/PD-L1 inhibitors plus VEGF targeted agents have shown positive results in various malignancies including HCC. The combination of atezolizumab plus bevacizumab is the new addition to the HCC treatment armamentarium following a pivotal study that demonstrated an improvement in OS over frontline sorafenib. Other novel immune-based approaches and oncolytic viruses are in the early phases of clinical evaluation. These innovative approaches enhance the intensity of cancer-directed immune responses and will potentially impact the outlook of this aggressive disease.

Keywords: CAR T cells; CTLA-4; DC vaccines; PD-L1; antigen peptide vaccines; cytokine induced killer cells; hepatocellular carcinoma; oncolytic viruses.

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
Y-K Kang, T Yau, +13 authors, M Kudo.
Ann Oncol, 2015 Sep 20; 26(12). PMID: 26386123
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Xiuqi Wu, Hong Luo, +7 authors, Zonghai Li.
Mol Ther, 2019 May 13; 27(8). PMID: 31078430    Free PMC article.
Cancer immunotherapy: the art of targeting the tumor immune microenvironment.
Jesse Lopes da Silva, Alexssandra Lima S Dos Santos, +3 authors, Andreia Cristina de Melo.
Cancer Chemother Pharmacol, 2019 Jun 27; 84(2). PMID: 31240384
Review.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Richard S Finn, Baek-Yeol Ryoo, +18 authors, KEYNOTE-240 investigators.
J Clin Oncol, 2019 Dec 04; 38(3). PMID: 31790344
Highly Cited.
Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma.
So Young Yoo, Su-Nam Jeong, Dae Hwan Kang, Jeong Heo.
Oncotarget, 2017 Oct 27; 8(42). PMID: 29069721    Free PMC article.
Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis.
Haiqing Wang, Aixiang Liu, +5 authors, Xiaoli Tang.
Dig Liver Dis, 2016 Oct 25; 48(11). PMID: 27481586
Systematic Review.
Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine.
R Bei, G J Mizejewski.
Curr Mol Med, 2011 Jun 29; 11(7). PMID: 21707514
Review.
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Christina L Roland, Sean P Dineen, +6 authors, Rolf A Brekken.
Mol Cancer Ther, 2009 Jul 02; 8(7). PMID: 19567820
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Sai Arun Batra, Purva Rathi, +10 authors, Andras Heczey.
Cancer Immunol Res, 2020 Jan 19; 8(3). PMID: 31953246
PD-1 and its ligands are important immune checkpoints in cancer.
Yinan Dong, Qian Sun, Xinwei Zhang.
Oncotarget, 2016 Dec 16; 8(2). PMID: 27974689    Free PMC article.
Highly Cited. Review.
Immunological landscape and immunotherapy of hepatocellular carcinoma.
Jesús Prieto, Ignacio Melero, Bruno Sangro.
Nat Rev Gastroenterol Hepatol, 2015 Oct 21; 12(12). PMID: 26484443
Highly Cited. Review.
Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.
Cheng-Maw Ho, Hui-Ling Chen, Rey-Heng Hu, Po-Huang Lee.
Ther Adv Med Oncol, 2019 May 09; 11. PMID: 31065295    Free PMC article.
Review.
Beyond the vascular profile: conventional DWI, IVIM and kurtosis in the assessment of hepatocellular carcinoma.
V Granata, R Fusco, +4 authors, A Petrillo.
Eur Rev Med Pharmacol Sci, 2020 Jul 25; 24(13). PMID: 32706066
Review.
Cytokines in clinical cancer immunotherapy.
Pedro Berraondo, Miguel F Sanmamed, +7 authors, Ignacio Melero.
Br J Cancer, 2018 Nov 11; 120(1). PMID: 30413827    Free PMC article.
Highly Cited. Review.
Immunotherapy against cancer-related viruses.
Haruko Tashiro, Malcolm K Brenner.
Cell Res, 2016 Dec 23; 27(1). PMID: 28008927    Free PMC article.
Review.
Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
Hidetaka Yasuoka, Akira Asai, +3 authors, Kazuhide Higuchi.
Sci Rep, 2020 Jun 27; 10(1). PMID: 32587357    Free PMC article.
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Austin G Duffy, Chi Ma, +16 authors, Tim F Greten.
Clin Cancer Res, 2017 May 04; 23(16). PMID: 28465443    Free PMC article.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, +18 authors, Ignacio Melero.
Lancet, 2017 Apr 25; 389(10088). PMID: 28434648    Free PMC article.
Highly Cited.
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Jeong Heo, Tony Reid, +23 authors, David H Kirn.
Nat Med, 2013 Feb 12; 19(3). PMID: 23396206    Free PMC article.
Highly Cited.
Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.
Zhiwu Jiang, Xiaofeng Jiang, +17 authors, Peng Li.
Front Immunol, 2017 Jan 27; 7. PMID: 28123387    Free PMC article.
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia.
J Immunother Cancer, 2018 Jan 24; 6(1). PMID: 29357948    Free PMC article.
Highly Cited. Review.
[Adoptive immunotherapy of malignancies].
I Zh Shubina, A G Bliumenberg, +2 authors, M V Kiselevskiĭ.
Vestn Ross Akad Med Nauk, 2007 Dec 18; (11). PMID: 18080522
Review.
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Philip J Johnson, Shukui Qin, +24 authors, Ann-Lii Cheng.
J Clin Oncol, 2013 Aug 28; 31(28). PMID: 23980084
Highly Cited.
Expansion of Tumor-Infiltrating Lymphocytes from Melanoma Tumors.
Stina Wickström, Tanja Lövgren.
Methods Mol Biol, 2019 Jan 23; 1913. PMID: 30666601
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.
Markus W Löffler, Christopher Mohr, +29 authors, Hans-Georg Rammensee.
Genome Med, 2019 May 02; 11(1). PMID: 31039795    Free PMC article.
Highly Cited.
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.
Gregory T Motz, Stephen P Santoro, +7 authors, George Coukos.
Nat Med, 2014 May 06; 20(6). PMID: 24793239    Free PMC article.
Highly Cited.
HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Elin M V Forsberg, Mattias F Lindberg, +8 authors, Jonas A Nilsson.
Cancer Res, 2019 Jan 10; 79(5). PMID: 30622115
Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor.
F Noyan, K Zimmermann, +10 authors, E Jaeckel.
Am J Transplant, 2016 Dec 21; 17(4). PMID: 27997080
Highly Cited.
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Andrew X Zhu, Masatoshi Kudo, +17 authors, Li-Tzong Chen.
JAMA, 2014 Jul 25; 312(1). PMID: 25058218
Highly Cited.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, +30 authors, CheckMate 214 Investigators.
N Engl J Med, 2018 Mar 22; 378(14). PMID: 29562145    Free PMC article.
Highly Cited.
Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.
Tim F Greten, Xin W Wang, Firouzeh Korangy.
Gut, 2015 Feb 11; 64(5). PMID: 25666193    Free PMC article.
Highly Cited. Review.
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges.
John D Martin, Giorgio Seano, Rakesh K Jain.
Annu Rev Physiol, 2019 Feb 12; 81. PMID: 30742782    Free PMC article.
Highly Cited. Review.
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
Ivy X Chen, Vikash P Chauhan, +7 authors, Rakesh K Jain.
Proc Natl Acad Sci U S A, 2019 Feb 01; 116(10). PMID: 30700545    Free PMC article.
Highly Cited.
Biomarkers of response to PD-1/PD-L1 inhibition.
Saman Maleki Vareki, Carmen Garrigós, Ignacio Duran.
Crit Rev Oncol Hematol, 2017 Jul 12; 116. PMID: 28693793
Highly Cited. Review.
The Role of Angiogenesis in Hepatocellular Carcinoma.
Michael A Morse, Weijing Sun, +4 authors, Richard S Finn.
Clin Cancer Res, 2018 Oct 03; 25(3). PMID: 30274981
Review.
Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma.
Keishi Fujiwara, Toshihiro Higashi, +9 authors, Yasushi Shiratori.
J Gastroenterol Hepatol, 2004 Sep 21; 19(10). PMID: 15377288
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2019 Sep 29; 381(16). PMID: 31562797
Highly Cited.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, +19 authors, IMbrave150 Investigators.
N Engl J Med, 2020 May 14; 382(20). PMID: 32402160
Designing and building oncolytic viruses.
Justin Maroun, Miguel Muñoz-Alía, +3 authors, Stephen Russell.
Future Virol, 2018 Feb 02; 12(4). PMID: 29387140    Free PMC article.
Highly Cited. Review.
In Vivo Estimation of Oncolytic Virus Populations within Tumors.
Mi-Yeon Jung, Chetan P Offord, +3 authors, David Dingli.
Cancer Res, 2018 Aug 18; 78(20). PMID: 30115692    Free PMC article.
Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.
Fujimasa Tada, Masanori Abe, +8 authors, Morikazu Onji.
Int J Oncol, 2012 Sep 14; 41(5). PMID: 22971679    Free PMC article.
Preparation and property analysis of a hepatocyte targeting pH-sensitive liposome.
Si-Yuan Wen, Xiao-Hong Wang, +2 authors, Sheng-Qi Wang.
World J Gastroenterol, 2004 Jan 13; 10(2). PMID: 14716832    Free PMC article.
A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma.
Li Xu, Jun Wang, +9 authors, Wan-Yee Lau.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141337    Free PMC article.
Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Cheng Chen, Kesang Li, +8 authors, Zonghai Li.
Cancer Immunol Immunother, 2016 Dec 31; 66(4). PMID: 28035433
Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.
Danijel Galun, Tatjana Srdic-Rajic, +2 authors, Marinko Zuvela.
J Hepatocell Carcinoma, 2017 Jul 27; 4. PMID: 28744453    Free PMC article.
Review.
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.
John P Veluchamy, Nina Kok, +3 authors, Jan Spanholtz.
Front Immunol, 2017 Jun 18; 8. PMID: 28620386    Free PMC article.
Highly Cited. Review.
BST2 Promotes Tumor Growth via Multiple Pathways in Hepatocellular Carcinoma.
Xiaoguang Xu, Yu Wang, +4 authors, Hongjin Zhang.
Cancer Invest, 2020 May 20; 38(5). PMID: 32427495
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Joseph A Fraietta, Simon F Lacey, +34 authors, J Joseph Melenhorst.
Nat Med, 2018 May 02; 24(5). PMID: 29713085    Free PMC article.
Highly Cited.
Viruses for tumor therapy.
John Bell, Grant McFadden.
Cell Host Microbe, 2014 Mar 19; 15(3). PMID: 24629333    Free PMC article.
Highly Cited. Review.
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
Shannon Burke, Amy Shergold, +6 authors, Danielle K Carroll.
Cancer Immunol Immunother, 2020 Feb 24; 69(6). PMID: 32088771    Free PMC article.
Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.
Nobuhiro Tsuchiya, Toshiaki Yoshikawa, +5 authors, Tetsuya Nakatsura.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123959    Free PMC article.
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
Priti S Hegde, Jeffrey J Wallin, Christoph Mancao.
Semin Cancer Biol, 2017 Dec 13; 52(Pt 2). PMID: 29229461
Review.
Trial watch: Dendritic cell-based interventions for cancer therapy.
Lorenzo Galluzzi, Laura Senovilla, +7 authors, Guido Kroemer.
Oncoimmunology, 2012 Nov 22; 1(7). PMID: 23170259    Free PMC article.
Highly Cited.
Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.
Yingjun Xie, Yien Xiang, +4 authors, Xuewen Zhang.
J Immunol Res, 2018 May 23; 2018. PMID: 29785403    Free PMC article.
Review.
Oncolytic Virotherapy: A Contest between Apples and Oranges.
Stephen J Russell, Kah-Whye Peng.
Mol Ther, 2017 Apr 11; 25(5). PMID: 28392162    Free PMC article.
Highly Cited. Review.
Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.
Yiming Meng, Zhifu Yu, +8 authors, Guirong Zhang.
Hum Vaccin Immunother, 2017 Mar 17; 13(6). PMID: 28301281    Free PMC article.
Review.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, +23 authors, Suresh S Ramalingam.
N Engl J Med, 2019 Sep 29; 381(21). PMID: 31562796
Highly Cited.
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Mario Sznol, Lieping Chen.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460533    Free PMC article.
Highly Cited.
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Armando Santoro, Lorenza Rimassa, +25 authors, Camillo Porta.
Lancet Oncol, 2012 Nov 28; 14(1). PMID: 23182627
Highly Cited.
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.
Lars Wallstabe, Claudia Göttlich, +8 authors, Michael Hudecek.
JCI Insight, 2019 Aug 16; 4(18). PMID: 31415244    Free PMC article.
Oncolytic virus therapy for cancer: the first wave of translational clinical trials.
Manish R Patel, Robert A Kratzke.
Transl Res, 2013 Jan 15; 161(4). PMID: 23313629
Review.
Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma.
T Tatsumi, T Takehara, +6 authors, N Hayashi.
Hepatology, 1997 May 01; 25(5). PMID: 9141426
Immunotherapy of cancer in 2012.
John M Kirkwood, Lisa H Butterfield, +3 authors, Soldano Ferrone.
CA Cancer J Clin, 2012 May 12; 62(5). PMID: 22576456    Free PMC article.
Highly Cited. Review.
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Feng Yu, Xingbing Wang, +3 authors, Xiao-Tong Song.
Mol Ther, 2013 Oct 19; 22(1). PMID: 24135899    Free PMC article.
Cellular therapies: Day by day, all the way.
Erden Atilla, Pelin Kilic, Gunhan Gurman.
Transfus Apher Sci, 2018 Apr 25; 57(2). PMID: 29685392
Review.
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Thibault Voron, Orianne Colussi, +15 authors, Magali Terme.
J Exp Med, 2015 Jan 21; 212(2). PMID: 25601652    Free PMC article.
Highly Cited.
Molecular basis of T cell inactivation by CTLA-4.
K M Lee, E Chuang, +7 authors, J A Bluestone.
Science, 1998 Dec 18; 282(5397). PMID: 9856951
Highly Cited.
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
N P Restifo, Y Kawakami, +4 authors, S A Rosenberg.
J Immunother Emphasis Tumor Immunol, 1993 Oct 01; 14(3). PMID: 8297900    Free PMC article.
Review.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, +43 authors, Luis A Diaz.
Science, 2017 Jun 10; 357(6349). PMID: 28596308    Free PMC article.
Highly Cited.
Interferon-stimulated genes: a complex web of host defenses.
William M Schneider, Meike Dittmann Chevillotte, Charles M Rice.
Annu Rev Immunol, 2014 Feb 22; 32. PMID: 24555472    Free PMC article.
Highly Cited. Review.
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Jeffrey J Wallin, Johanna C Bendell, +19 authors, David F McDermott.
Nat Commun, 2016 Aug 31; 7. PMID: 27571927    Free PMC article.
Highly Cited.
Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Xiao-Ting Zhu, Ji-Hang Yuan, +2 authors, Xiao-Yang Cheng.
FEBS J, 2016 Oct 21; 283(20). PMID: 27573079
Highly Cited.
Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options.
Andreas Koulouris, Christos Tsagkaris, +3 authors, Michail Nikolaou.
J Hepatocell Carcinoma, 2021 May 21; 8. PMID: 34012929    Free PMC article.
Review.
Natural Killer-Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy.
Valentina Cazzetta, Sara Franzese, +3 authors, Domenico Mavilio.
Cancers (Basel), 2021 Jun 03; 13(9). PMID: 34062821    Free PMC article.
Review.
Cellular based treatment modalities for unresectable hepatocellular carcinoma.
Konstantinos Damiris, Hamza Abbad, Nikolaos Pyrsopoulos.
World J Clin Oncol, 2021 Jun 17; 12(5). PMID: 34131562    Free PMC article.
Review.
The Immunology of Hepatocellular Carcinoma.
Gbemisola Lawal, Yao Xiao, +4 authors, Timothy M Pawlik.
Vaccines (Basel), 2021 Oct 27; 9(10). PMID: 34696292    Free PMC article.
Review.
Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study.
Jinliang Zhang, Xihao Zhang, +4 authors, Ti Zhang.
Front Oncol, 2021 Dec 07; 11. PMID: 34868921    Free PMC article.
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, +4 authors, Giovanni Brandi.
Front Oncol, 2022 Jan 04; 11. PMID: 34976841    Free PMC article.
Review.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.
Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Yizhou Wang, Feihong Song, Xiaofeng Zhang, Cheng Yang.
Oxid Med Cell Longev, 2022 May 11; 2022. PMID: 35535359    Free PMC article.